Physician profile
Peter E Hoepfner
NPI 1306876297
$34,425.60
in general payments reported to CMS, 2019-2025
15 companies · $99.84 in 2025
The $99.84 reported for 2025 was less than what a typical Hand Surgery provider received nationally (typical 2025 total: $270).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $12K · 2021: $407 · 2022: $8,279 · 2023: $183 · 2024: $385 · 2025: $99.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632 · Travel and Lodging: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.47 |
| Travel and Lodging | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $22,940.37 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $7,229.23 | 2019-2024 | Comprehensive Shoulder System |
| Medwest Associates | $2,255.65 | 2019-2023 | |
| Anika Therapeutics, INC. | $1,128.24 | 2022 | |
| Acumed LLC | $185.35 | 2024-2025 | Acumed, Nanophix Implant, Innate Implant |
| Biotissue Holdings INC. | $161.19 | 2021 | |
| Amgen INC. | $124.26 | 2024 | Krystexxa |
| Axogen | $112.84 | 2023 | Avance Nerve Graft |
| Bioventus LLC | $84.47 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $47.95 | 2024 | Exparel, Zilretta |
| Ferring Pharmaceuticals INC. | $46.69 | 2024-2025 | Euflexxa |
| Stryker Corporation | $45.27 | 2021-2023 | Axsos, Hoffmann, T2 Alpha |
| Djo, LLC | $27.58 | 2024 | Cmf |
| Globus Medical, INC. | $18.39 | 2021 | |
| Lightbody Medical Technologies INC | $18.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hoepfner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.